Literature DB >> 25534738

Fluoroquinolone resistance does not impose a cost on the fitness of Clostridium difficile in vitro.

François Wasels1, Sarah A Kuehne2, Stephen T Cartman2, Patrizia Spigaglia3, Fabrizio Barbanti1, Nigel P Minton2, Paola Mastrantonio1.   

Abstract

Point mutations conferring resistance to fluoroquinolones were introduced in the gyr genes of the reference strain Clostridium difficile 630. Only mutants with the substitution Thr-82→Ile in GyrA, which characterizes the hypervirulent epidemic clone III/027/NAP1, were resistant to all fluoroquinolones tested. The absence of a fitness cost in vitro for the most frequent mutations detected in resistant clinical isolates suggests that resistance will be maintained even in the absence of antibiotic pressure.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25534738      PMCID: PMC4325769          DOI: 10.1128/AAC.04503-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Conjugative plasmid transfer from Escherichia coli to Clostridium acetobutylicum.

Authors:  D R Williams; D I Young; M Young
Journal:  J Gen Microbiol       Date:  1990-05

3.  High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.

Authors:  Denise Drudy; Teresa Quinn; Rebecca O'Mahony; Lorraine Kyne; Peadar O'Gaora; Séamus Fanning
Journal:  J Antimicrob Chemother       Date:  2006-10-03       Impact factor: 5.790

4.  Transposition of ampicillin resistance from RP4 to other replicons.

Authors:  R W Hedges; A E Jacob
Journal:  Mol Gen Genet       Date:  1974

5.  gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.

Authors:  Larbi Dridi; Jacques Tankovic; Béatrice Burghoffer; Frédéric Barbut; Jean-Claude Petit
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.

Authors:  G Ackermann; Y J Tang; R Kueper; P Heisig; A C Rodloff; J Silva; S H Cohen
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

7.  Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.

Authors:  Patricia Komp Lindgren; Linda L Marcusson; Dorthe Sandvang; Niels Frimodt-Møller; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa.

Authors:  Elisabeth Kugelberg; Sonja Löfmark; Bengt Wretlind; Dan I Andersson
Journal:  J Antimicrob Chemother       Date:  2004-12-01       Impact factor: 5.790

9.  Investigation of an outbreak of antibiotic-associated colitis by various typing methods.

Authors:  J Wüst; N M Sullivan; U Hardegger; T D Wilkins
Journal:  J Clin Microbiol       Date:  1982-12       Impact factor: 5.948

10.  Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe.

Authors:  Patrizia Spigaglia; Fabrizio Barbanti; Paola Mastrantonio; Jon S Brazier; Frédéric Barbut; Michel Delmée; Ed Kuijper; Ian R Poxton
Journal:  J Med Microbiol       Date:  2008-06       Impact factor: 2.472

View more
  16 in total

Review 1.  Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.

Authors:  Patrizia Spigaglia
Journal:  Ther Adv Infect Dis       Date:  2016-02

Review 2.  Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.

Authors:  Chetna Dureja; Abiola O Olaitan; Julian G Hurdle
Journal:  Curr Opin Microbiol       Date:  2022-01-22       Impact factor: 7.584

Review 3.  Antimicrobial resistance in Clostridioides difficile.

Authors:  Keeley O'Grady; Daniel R Knight; Thomas V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-24       Impact factor: 3.267

Review 4.  Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria.

Authors:  Miklos Fuzi; Dora Szabo; Rita Csercsik
Journal:  Front Microbiol       Date:  2017-11-16       Impact factor: 5.640

5.  Clostridium difficile in patients attending tuberculosis hospitals in Cape Town, South Africa, 2014-2015.

Authors:  Brian R Kullin; Sharon Reid; Valerie Abratt
Journal:  Afr J Lab Med       Date:  2018-12-06

6.  Involvement of the RND efflux pump transporter SmeH in the acquisition of resistance to ceftazidime in Stenotrophomonas maltophilia.

Authors:  Paula Blanco; Fernando Corona; José Luis Martínez
Journal:  Sci Rep       Date:  2019-03-20       Impact factor: 4.379

7.  Recent advances in the treatment of C. difficile using biotherapeutic agents.

Authors:  Vo Van Giau; Hyon Lee; Seong Soo A An; John Hulme
Journal:  Infect Drug Resist       Date:  2019-06-10       Impact factor: 4.003

Review 8.  Mechanisms of antibiotic resistance of Clostridioides difficile.

Authors:  Ishani Wickramage; Patrizia Spigaglia; Xingmin Sun
Journal:  J Antimicrob Chemother       Date:  2021-11-12       Impact factor: 5.758

9.  Fitness Cost of Fluoroquinolone Resistance in Clinical Isolates of Pseudomonas aeruginosa Differs by Type III Secretion Genotype.

Authors:  Melissa Agnello; Steven E Finkel; Annie Wong-Beringer
Journal:  Front Microbiol       Date:  2016-10-04       Impact factor: 5.640

Review 10.  Dissimilar Fitness Associated with Resistance to Fluoroquinolones Influences Clonal Dynamics of Various Multiresistant Bacteria.

Authors:  Miklos Fuzi
Journal:  Front Microbiol       Date:  2016-07-07       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.